Highlights
- •The effect of the metabolic syndrome (MS) on prognosis in the catheterization laboratory is controversial.
- •Patients with MS had more CAD, ACS, and elevated atherogenic biomarkers.
- •MS had a significant effect on mortality in stable patients and not in patients with ACS.
Past studies examining the effects of the metabolic syndrome (MS) on prognosis in
postangiography patients were limited in size or were controversial in results. The
aim of the study was to examine the association of the MS and the risk for long-term
mortality in a large cohort of patients undergoing coronary angiography for various
clinical indications. Medical history, physical examination, and laboratory values
were used to diagnose patients with the MS. Cox regression models were used to analyze
the effect of MS on long-term all-cause mortality. We prospectively recruited 3,525
consecutive patients with a mean age of 66 ± 22 years (range 24 to 97) and 72% men.
Thirty percent of the cohort had MS. Patients with MS were more likely to have advanced
coronary artery disease and acute coronary syndrome (p <0.001). Patients with MS had
more abnormalities in their metabolic and inflammatory biomarkers regardless of their
clinical presentation. A total of 495 deaths occurred during a mean follow-up period
of 1,614 ± 709 days (median 1,780, interquartile range 1,030 to 2,178). MS was associated
with an increased risk of death in the general cohort (hazard ratio [HR] 1.27, 95%
confidence interval [CI] 1.01 to 1.56, p = 0.02). MS had a significant effect on mortality
in stable patients (HR 1.55, 95% CI 1.1 to 2.18, p = 0.01), whereas it did not have
a significant effect on mortality in patients with acute coronary syndrome (HR 1.11,
95% CI 0.86 to 1.44, p = 0.42). In conclusion, MS is associated with increased mortality
in postangiography patients. Its adverse outcome is mainly seen in patients with stable
angina.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Admission glucose, fasting glucose, HbA1c levels and the SYNTAX score in non-diabetic patients undergoing coronary angiography.Clin Res Cardiol. 2014; 103: 223-227
- Lack of correlation between coronary blood flow and carotid intima media thickness.Clin Hemorheol Microcirc. 2014; 56: 371-381
- Inverse correlation between coronary and retinal blood flows in patients with normal coronary arteries and slow coronary blood flow.Atherosclerosis. 2014; 232: 149-154
- Hyperglycemia in patients referred for cardiac catheterization is associated with preexisting diabetes rather than a stress-related phenomenon: a prospective cross-sectional study.Clin Cardiol. 2014; 37: 479-484
- Higher neutrophil/lymphocyte ratio is related to lower ejection fraction and higher long-term all-cause mortality in ST-elevation myocardial infarction patients.Can J Cardiol. 2014; 30: 1177-1182
- Anemia and inflammation have an additive value in risk stratification of patients undergoing coronary interventions.J Cardiovasc Med (Hagerstown, Md). 2013; (In press)
- Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines.Cardiovasc Diabetol. 2013; 12: 140
- The reliability and prognosis of in-hospital diagnosis of metabolic syndrome in the setting of acute myocardial infarction.J Am Coll Cardiol. 2013; 62: 704-708
- Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention.Circulation. 2011; 124: 704-711
- Metabolic syndrome: clinical and angiographic impact on patients with acute coronary syndrome.Cir Cir. 2010; 78: 113-120
- Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes.JACC Cardiovasc Imaging. 2012; 5: S42-S52
- Metabolic syndrome and outcome in patients with acute myocardial infarction.Acta Clin Croat. 2011; 50: 193-199
- Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents.Am J Cardiol. 2007; 100: 1347-1352
- Intima-media thickness correlates with features of metabolic syndrome in young people with a clinical diagnosis of familial hypercholesterolaemia.Kardiol Pol. 2013; 71: 566-572
- Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS).Am J Cardiol. 2009; 104: 1457-1464
- Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010).Am J Cardiol. 2013; 112: 1126-1132
- Obesity and the metabolic syndrome in patients with acute myocardial infarction.Int J Cardiol. 2010; 144: 450-451
- Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.Circ J. 2012; 76: 2840-2847
- Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness.Diabetes Care. 2005; 28: 391-397
- Weight reduction in patients with coronary artery disease: comparison of traditional Tibetan medicine and Western diet.Int J Cardiol. 2013; 168: 1509-1515
- Self-reported prevalence and awareness of metabolic syndrome: findings from SHIELD.Int J Clin Pract. 2008; 62: 1168-1176
Article Info
Publication History
Published online: November 14, 2014
Accepted:
October 28,
2014
Received in revised form:
October 28,
2014
Received:
September 11,
2014
Footnotes
This study was supported by internal departmental resources.
See page 286 for disclosure information.
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
